- Home
- NIO vs LEGN Comparison
NIO vs LEGN Comparison
Compare NIO & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIO
- LEGN
- Stock Information
- Founded
- NIO 2014
- LEGN 2014
- Country
- NIO China
- LEGN United States
- Employees
- NIO N/A
- LEGN N/A
- Industry
- NIO Auto Manufacturing
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- NIO Consumer Discretionary
- LEGN Health Care
- Exchange
- NIO Nasdaq
- LEGN Nasdaq
- Market Cap
- NIO 7.4B
- LEGN 7.0B
- IPO Year
- NIO 2018
- LEGN 2020
- Fundamental
- Price
- NIO $4.20
- LEGN $33.10
- Analyst Decision
- NIO Hold
- LEGN Strong Buy
- Analyst Count
- NIO 6
- LEGN 13
- Target Price
- NIO $5.05
- LEGN $79.42
- AVG Volume (30 Days)
- NIO 37.0M
- LEGN 1.5M
- Earning Date
- NIO 06-05-2025
- LEGN 05-13-2025
- Dividend Yield
- NIO N/A
- LEGN N/A
- EPS Growth
- NIO N/A
- LEGN N/A
- EPS
- NIO N/A
- LEGN N/A
- Revenue
- NIO $9,005,433,398.00
- LEGN $627,241,000.00
- Revenue This Year
- NIO $37.33
- LEGN $65.96
- Revenue Next Year
- NIO $25.67
- LEGN $52.55
- P/E Ratio
- NIO N/A
- LEGN N/A
- Revenue Growth
- NIO 18.18
- LEGN 119.97
- 52 Week Low
- NIO $3.02
- LEGN $29.27
- 52 Week High
- NIO $7.71
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- NIO 56.91
- LEGN 45.81
- Support Level
- NIO $3.82
- LEGN $30.25
- Resistance Level
- NIO $4.15
- LEGN $32.97
- Average True Range (ATR)
- NIO 0.16
- LEGN 1.39
- MACD
- NIO 0.03
- LEGN -0.13
- Stochastic Oscillator
- NIO 58.87
- LEGN 40.52
About NIO NIO Inc. American depositary shares each representing one ordinary share
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold around 222,000 EVs in 2024, accounting for about 2% of the China passenger new energy vehicle market.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.